BeOne Medicines ((ONC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: BeOne Medicines is conducting a Phase 1a/1b clinical study titled A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-75202, Alone and in Combination With Other Agents in Patients With Advanced Solid Tumors. The study aims to assess the safety and preliminary antitumor activity of BG-75202, a KAT6A/B inhibitor, in patients with breast cancer and other advanced solid tumors.
Intervention/Treatment: The study tests BG-75202, administered orally, both as a monotherapy and in combination with other drugs such as estrogen receptor antagonists, CDK4 inhibitors, and aromatase inhibitors, to evaluate its efficacy in treating advanced solid tumors.
Study Design: This interventional study is non-randomized and follows a sequential intervention model. It is open-label, meaning there is no masking, and its primary purpose is treatment-focused, aiming to optimize dosing and assess safety and efficacy.
Study Timeline: The study is set to begin on October 28, 2025, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on October 28, 2025, marking the study as not yet recruiting.
Market Implications: The initiation of this study could positively influence BeOne Medicines’ stock performance by showcasing their commitment to innovative cancer treatments. Investor sentiment may be bolstered by the potential of BG-75202 to address unmet needs in advanced solid tumor therapies, although competition in the oncology sector remains strong.
The study is ongoing, with further details available on the ClinicalTrials portal.